The DOI matches its Crossref record; 105 of the 105 references it cites were found in a registry or an index.
Overcoming cellular barriers for RNA therapeutics
Abstract
RNA-based therapeutics, such as small-interfering (siRNAs), microRNAs (miRNAs), antisense oligonucleotides (ASOs), aptamers, synthetic mRNAs and CRISPR-Cas9, have great potential to target a large part of the currently undruggable genes and gene products and to generate entirely new therapeutic paradigms in disease, ranging from cancer to pandemic influenza to Alzheimer's disease. However, for these RNA modalities to reach their full potential, they first need to overcome a billion years of evolutionary defenses that have kept RNAs on the outside of cells from invading the inside of cells. Overcoming the lipid bilayer to deliver RNA into cells has remained the major problem to solve for widespread development of RNA therapeutics, but recent chemistry advances have begun to penetrate this evolutionary armor.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As an emerging programmable gene interference technique, siRNA offers high specificity and flexibility in targeting the diseased human genome [236].”
From Emerging role of exosomes in cancer therapy: progress and challenges (2025) · cites this paper as [236]
In the citing paper
“Many obstacles still exist despite the rise in studies on delivery platforms, including toxicity and the precise distribution of mRNA to extrahepatic organs [13, 14].”
From Exosome for mRNA delivery: Strategies and therapeutic applications (2024) · cites this paper as [13]
In the citing paper
“Independent of the administration route, several evolutionary barriers are designed to prevent any intrusion of foreign nucleic acids and thus limit the delivery of exogenous mRNA [74].”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [74]
In the citing paper
“For instance, RNA interference (RNAi) technology enables the downregulation of disease related genes and protein expression; mRNA mediates the expression and supplementation of therapeutic proteins; the CRISPR gene editing system facilitates gene engineering in vivo or through cell engineering ex vivo.[6, 9, 11, 17–20]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [19]
In the citing paper
“For instance, RNA interference (RNAi) technology enables the downregulation of disease related genes and protein expression; mRNA mediates the expression and supplementation of therapeutic proteins; the CRISPR gene editing system facilitates gene engineering in vivo or through cell engineering ex vivo.[6, 9, 11, 17–20]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [19]
In the citing paper
“For instance, RNA interference (RNAi) technology enables the downregulation of disease related genes and protein expression; mRNA mediates the expression and supplementation of therapeutic proteins; the CRISPR gene editing system facilitates gene engineering in vivo or through cell engineering ex vivo.[6, 9, 11, 17–20]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [19]
In the citing paper
“With the development of chemical modifications on RNA molecules, modified siRNA are reported to remain intact for long durations under circulation, which provides the possibility of delivering siRNA without the shielding of nanoparticles.[19, 75, 76]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [19]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., & Tuschl, T. (2001) · Nature · doi:10.1038/35078107 · Cited by 9,456
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
Doherty, G. J., & McMahon, H. T. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.081307.110540 · Cited by 3,075
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Research works printed but not linked: 2
- Rich, A. in Horizons In Biochemistry (eds. Kasha, M. & Pullman, B.) 103–126 (Academic Press, New York, 1962).
- Cummings, R. & McEver, R. in Essentials of Glycobiology. 2nd edn. (eds. Varki, A. et al.) Chapter 31 (Cold Spring Harbor (NY); Cold Spring Harbor Laboratory Press, 2009).
Cited by
Sorted by citations
Items 401–500 of 1,000
Stojković, M., Han, D., Jeong, M., Stojković, P., & Stanković, K. M. (2021) · Stem Cells · doi:10.1002/stem.3353 · Cited by 34
Chun, Y. Y., Tan, W., Vos, M. I. G., Chan, W. K., Tey, H. L., Tan, N. S., & Tan, T. T. Y. (2022) · Biomaterials Science · doi:10.1039/d2bm00572g · Cited by 33
The role of noncoding RNAs in metabolic reprogramming of cancer cells
Safi, A., Saberiyan, M., Sanaei, M., Adelian, S., Asl, F. D., Zeinaly, M., Shamsi, M., & Ahmadi, R. (2023) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-023-00447-8 · Cited by 36
Developing Folate-Conjugated miR-34a Therapeutic for Prostate Cancer: Challenges and Promises
Li, W., Wang, Y., Liu, X., Wu, S., Wang, M., Turowski, S. G., Spernyak, J. A., Tracz, A., Abdelaal, A. M., Sudarshan, K., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042123 · Cited by 33
Long, D., Deng, Z., Zhao, X., Xu, Y., Li, W. H., Mo, X., Zhong, Y., Li, M., He, A., Zhang, Z., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122903 · Cited by 32
GalNac-siRNA conjugate delivery technology promotes the treatment of typical chronic liver diseases
Qin, Z.-X., Zuo, L., Zeng, Z., Ma, R., Xie, W., Zhu, X., & Zhou, X. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2025.2466767 · Cited by 32
At the bench: Engineering the next generation of cancer vaccines
Shae, D., Baljon, J. J., Wehbe, M., Becker, K. W., Sheehy, T. L., & Wilson, J. T. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.5bt0119-016r · Cited by 32
Lu, Z.-D., Chen, Y., Shen, S., Xu, C., & Wang, J. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c08329 · Cited by 33
Engineered Protein Nanocages for Concurrent RNA and Protein Packaging In Vivo
Kwon, S., & Giessen, T. W. (2022) · ACS Synthetic Biology · doi:10.1021/acssynbio.2c00391 · Cited by 31
Gutiérrez-Lovera, C., Vázquez-Ríos, A. J., Guerra‐Varela, J., Sanchez, L. E., & la Fuente, M. D. (2017) · Genes · doi:10.3390/genes8120349 · Cited by 32
Functional extracellular vesicles aplenty
Zickler, A. M., & Andaloussi, S. E. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0507-z · Cited by 33
McCann, J. L., Sosa‐Miranda, C. D., Guo, H., Reshke, R., Savard, A., Buzatto, A. Z., Taylor, J. A., Li, L., & Gibbings, D. (2022) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12220 · Cited by 36
Dawn of Epitranscriptomic Medicine
Gatsiou, A., & Stellos, K. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.118.001927 · Cited by 31
Biswas, A., Chakraborty, K., Dutta, C., Mukherjee, S., Gayen, P., Jan, S., Mallick, A. M., Bhattacharyya, D., & Roy, R. S. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b13794 · Cited by 31
A Light‐Triggerable Nanoparticle Library for the Controlled Release of Non‐Coding RNAs
Blersch, J., Francisco, V., Rebelo, C., Jiménez‐Balsa, A., Antunes, H., Gonzato, C., Pinto, S., Simões, S. M. N., Liedl, K. R., Haupt, K., et al. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201911398 · Cited by 32
Enzymatic Synthesis of Designer DNA Using Cyclic Reversible Termination and a Universal Template
Hoff, K., Halpain, M., Garbagnati, G. F., Edwards, J. S., & Zhou, W. (2020) · ACS Synthetic Biology · doi:10.1021/acssynbio.9b00315 · Cited by 30
Lin, S., Yu, Z., Guan, Y., & Yi, H. (2020) · Cancer Management and Research · doi:10.2147/cmar.s241519 · Cited by 31
Spencer, D. S., Shodeinde, A. B., Beckman, D. W., Luu, B. C., Hodges, H. R., & Peppas, N. A. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.03.004 · Cited by 32
Research progress of tumor targeted drug delivery based on PD-1/PD-L1
Liu, D., Gao, S., Zhai, Y., Yang, X., & Zhai, G. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121527 · Cited by 30
Small Activating RNA Modulation of the G Protein‐Coupled Receptor for Cancer Treatment
Xiong, Y., Ke, R., Zhang, Q., Lan, W., Yuan, W., Chan, K. N. I., Roussel, T., Jiang, Y., Wu, J., Liu, S., et al. (2022) · Advanced Science · doi:10.1002/advs.202200562 · Cited by 32
Bai, X., Chen, Y., Zou, M., Li, C., Zhang, Y., Li, M., Cheng, S., & Zhang, X. (2022) · ACS Nano · doi:10.1021/acsnano.2c06871 · Cited by 31
Long Non-Coding RNAs (lncRNAs) as Regulators of the PI3K/AKT/mTOR Pathway in Gastric Carcinoma
Riquelme, I., Pérez-Moreno, P., Mora‐Lagos, B., Ili, C., Brebi, P., & Roa, J. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076294 · Cited by 32
siRNA therapeutics: insights, challenges, remedies and future prospects
Khan, S., Rehman, U., Parveen, N., Kumar, S., Baboota, S., & Ali, J. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2251890 · Cited by 34
Finicle, B. T., Eckenstein, K. H., Revenko, A. S., Anderson, B. A., Wan, W. B., McCracken, A. N., Gil, D., Fruman, D. A., Hanessian, S., Seth, P. P., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad023 · Cited by 30
Advances in nucleic acid-targeted therapies for cardiovascular disease prevention
Makhmudova, U., Steinhagen‐Thiessen, E., Volpe, M., & Landmesser, U. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae136 · Cited by 31
Bioengineered Nanomaterials for siRNA Therapy of Chemoresistant Cancers
Sanati, M., Figueroa‐Espada, C. G., Han, E. L., Mitchell, M. J., & Yavari, S. A. (2024) · ACS Nano · doi:10.1021/acsnano.4c11259 · Cited by 33
Riquelme, I., Pérez, P. E., Letelier, P. J., Brebi, P., & Roa, J. C. (2021) · Cancers · doi:10.3390/cancers14010202 · Cited by 31
Nucleic acid-based artificial nanocarriers for gene therapy
Zhu, L., Luo, J. S., & Ren, K. (2022) · Journal of Materials Chemistry B · doi:10.1039/d2tb01179d · Cited by 31
Current RNA strategies in treating cardiovascular diseases
Chia, S. P. S., Pang, J. K. S., & Soh, B.-S. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.028 · Cited by 32
Wu, X., Zheng, Y., Yang, D., Chen, T., Feng, B., Weng, J., Wang, J., Zhang, K., & Zhang, X. (2018) · Journal of Materials Chemistry B · doi:10.1039/c8tb02463d · Cited by 29
Engineering polyphenol-based carriers for nucleic acid delivery
Shui, M., Chen, Z., Chen, Y., Yuan, Q., Li, H., Vong, C. T., Farag, M. A., & Wang, S. (2023) · Theranostics · doi:10.7150/thno.81604 · Cited by 29
Yadav, D., & Malviya, R. (2023) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2023.100163 · Cited by 29
Virus Mimetic Framework DNA as a Non-LNP Gene Carrier for Modulated Cell Endocytosis and Apoptosis
Shi, Q., Wu, Y., Xu, Y., Bao, M., Chen, X., Huang, K., Yang, Q., & Yang, Y. (2023) · ACS Nano · doi:10.1021/acsnano.2c09772 · Cited by 28
Aptamer-based approaches in leukemia: a paradigm shift in targeted therapy
Bayani, A., Abosaoda, M. K., Rizaev, J. A., Nazari, M., Jafari, Z., & Samarkhazan, H. S. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01724-w · Cited by 29
Cui, L., Cui, Y., Liu, J., Li, W., Wu, M., Wei, X., Lai, Y., & Mi, P. (2025) · Nature Communications · doi:10.1038/s41467-025-61230-1 · Cited by 34
Role of Gene Therapy in Pancreatic Cancer—A Review
Sato‐Dahlman, M., Wirth, K. M., & Yamamoto, M. (2018) · Cancers · doi:10.3390/cancers10040103 · Cited by 28
Site Selective Antibody-Oligonucleotide Conjugation via Microbial Transglutaminase
Huggins, I. J., Medina, C. A., Springer, A. D., van den Berg, A., Jadhav, S. G., Cui, X.-S., & Dowdy, S. F. (2019) · Molecules · doi:10.3390/molecules24183287 · Cited by 28
Self-citationWeidle, U. H., SCHMID, D., Birzele, F., & Brinkmann, U. (2019) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20163 · Cited by 28
Ross‐Thriepland, D., Bornot, A., Butler, L., Desai, A. S., Jaiswal, H., Peel, S. E., Hunter, M. R., Odunze, U., Isherwood, B. J., & Gianni, D. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220925770 · Cited by 26
Research progress and prospects for the use of aptamers in aquaculture biosecurity
Yu, Q. C., Liu, M., Wei, S., Qin, X., Qin, Q., & Li, P. (2020) · Aquaculture · doi:10.1016/j.aquaculture.2020.736257 · Cited by 28
Oligonucleotide-Based Therapies for Renal Diseases
Cartón‐García, F., Saande, C. J., Meraviglia-Crivelli, D., Aldabe, R., & Pastor, F. (2021) · Biomedicines · doi:10.3390/biomedicines9030303 · Cited by 28
Fahoum, F., & Eyal, S. (2023) · Epilepsia · doi:10.1111/epi.17625 · Cited by 27
Nucleic acid amphiphiles: Synthesis, properties, and applications
Gubu, A., Zhang, X., Lü, A., Zhang, B., Ma, Y., & Zhang, G. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.05.022 · Cited by 30
Gene Therapy for Inherited Hearing Loss: Updates and Remaining Challenges
Hahn, R., & Avraham, K. B. (2023) · Audiology Research · doi:10.3390/audiolres13060083 · Cited by 29
Comparison of different chemically modified inhibitors of miR-199b in vivo
Duygu, B., Juni, R. P., Ottaviani, L., Bitsch, N. J. J. E., Wit, J. B. M., Windt, L. J. D., & Martins, P. A. D. C. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.11.013 · Cited by 28
Kumar, V., Wahane, A. V., Gupta, A., Manautou, J. E., & Bahal, R. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202202859 · Cited by 28
Oligonucleotide therapeutics and their chemical modification strategies for clinical applications
Kim, H., Kim, S., Lee, D., Lee, D., Yoon, J., & Lee, H. (2024) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-024-00669-8 · Cited by 30
Advanced gene therapy system for the treatment of solid tumour: A review
Ma, Y., Liao, J., Cheng, H., Yang, Q., & Yang, H. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101138 · Cited by 28
Exosomes and solid cancer therapy: where are we now?
Zemánek, T., Danišovič, Ľ., & Nicodemou, A. (2025) · Medical Oncology · doi:10.1007/s12032-025-02626-3 · Cited by 32
Inhibition of glioma growth by a GOLPH3 siRNA-loaded cationic liposomes
Yuan, Z., Zhao, L., Zhang, Y., Li, S., Pan, B., Hua, L., Wang, Z., Ye, C., Lu, J. L., Yu, R., et al. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2966-6 · Cited by 28
The Complex Network between MYC Oncogene and microRNAs in Gastric Cancer: An Overview
Anauate, A. C., Leal, M. F., Calcagno, D. Q., Gigek, C. O., Karia, B. T. R., Wisnieski, F., Santos, L. C., Chen, E., Burbano, R. M. R., & Smith, M. D. A. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051782 · Cited by 27
Ionizable drug delivery systems for efficient and selective gene therapy
Zhang, Y., Guo, R., Chen, Y., Li, T., Du, W.-Z., Xiang, R., Guan, J., Li, Y., Huang, Y., Yu, Z., et al. (2023) · Military Medical Research · doi:10.1186/s40779-023-00445-z · Cited by 27
Insight into the siRNA transmembrane delivery—From cholesterol conjugating to tagging
Zheng, Y., & Tai, W. (2019) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1606 · Cited by 28
Advances in quantum dot-mediated siRNA delivery
He, Z., Jin, Z., Zhan, M., Qin, Z., Li, Z., & Xu, T. (2017) · Chinese Chemical Letters · doi:10.1016/j.cclet.2017.07.012 · Cited by 26
Zhang, J., Liu, Z., Pei, Y., Yang, W. K., Xie, C., & Long, S. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2475-1 · Cited by 26
RetractedA Review of pH‐Responsive Organic–Inorganic Hybrid Nanoparticles for RNAi‐Based Therapeutics
Wang, L., & Yan, Y. (2021) · Macromolecular Bioscience · doi:10.1002/mabi.202100183 · Cited by 27
Veeren, A., Ogunyankin, M. O., Shin, J. E., & Zasadzinski, J. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040701 · Cited by 26
Zhang, H., Ding, F., Zhu, Z., Sun, Q., & Yang, C. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122489 · Cited by 25
Feichtenschlager, V., Zheng, Y. J., Ho, W. W.-S., Chen, L.-N., Callanan, C., Chen, C., Lee, A., Ortiz, J., Rappersberger, K., & Ortiz‐Urda, S. (2023) · Oncotarget · doi:10.18632/oncotarget.28447 · Cited by 26
Overview of DNA Self-Assembling: Progresses in Biomedical Applications
Jorge, A. F., & Eritja, R. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10040268 · Cited by 27
Setbacks shadow microRNA therapies in the clinic
Jones, D. (2018) · Nature Biotechnology · doi:10.1038/nbt1018-909 · Cited by 26
Ayyar, V. S., & Song, D. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.10.026 · Cited by 26
Jiang, H., Qin, H., Yang, Q., Huang, L., Liang, X. Q., Wang, C., Moro, A., Xu, S., & Wei, Q. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02561-x · Cited by 25
Jin, Y., Wang, X., Kromer, A. P. E., Müller, J. T., Zimmermann, C. M., Xu, Z., Hartschuh, A., Adams, F., & Merkel, O. M. (2024) · Biomacromolecules · doi:10.1021/acs.biomac.4c00283 · Cited by 25
Liver-targeting chimeras as a potential modality for the treatment of liver diseases
Chen, C., Pan, Y., Yang, X., Li, H., Cai, X., He, S., Wang, Q., Yang, Y., Zheng, R., Li, H., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.08.044 · Cited by 25
Clinical advancements in mRNA vaccines against viral infections
Fatima, M. T., Park, P., & Hong, K. (2024) · Clinical Immunology · doi:10.1016/j.clim.2024.110424 · Cited by 25
Nano Approaches to Nucleic Acid Delivery: Barriers, Solutions, and Current Landscape
Gonzalez, J. C., Park, K. W., Evans, D. B., Sharma, R. B., Sahaym, O., Gopalakrishnan, S., Dar, A. I., Valdez, T. A., & Sharma, A. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70010 · Cited by 31
Downregulation of microRNA-21 inhibited radiation-resistance of esophageal squamous cell carcinoma
Fang, L., Lv, J., Liang, L., Wang, J., Li, C.-R., Sun, L., & Li, T. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0502-6 · Cited by 25
Aptamers for Targeted Delivery: Current Challenges and Future Opportunities
Chandola, C., & Neerathilingam, M. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.84217 · Cited by 25
Chemical strategies for strand selection in short-interfering RNAs
Varley, A., & Desaulniers, J. (2021) · RSC Advances · doi:10.1039/d0ra07747j · Cited by 26
Chen, M., Dong, C., & Shi, S. (2021) · Advanced Materials Technologies · doi:10.1002/admt.202001236 · Cited by 25
Kang, T., Ni, J., Li, T., Wang, J., Li, Z., Li, Y., Zha, M., Zhang, C., Wu, X., Guo, H., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120907 · Cited by 25
Sonntag, T., Froemel, F., Stamer, W. D., Ohlmann, A., Fuchshofer, R., & Breunig, M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060901 · Cited by 25
Singh, R., Zogg, H., & Ro, S. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11101021 · Cited by 25
Orafidiya, F. A., Deng, L., Bevan, C. L., & Fletcher, C. E. (2022) · Cancers · doi:10.3390/cancers14030755 · Cited by 25
Preclinical Safety Assessment of Therapeutic Oligonucleotides
Andersson, P. U. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2010-6_25 · Cited by 28
Safe and Effective Delivery of mRNA Using Modified PEI-Based Lipopolymers
Wang, H., Liu, X., Ai, X., Remant-Bahadur, K. C., Dick, T. A., Yan, B., Lu, T., Zhou, X., Luo, R., Liu, M., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020410 · Cited by 25
Advances in Focused Ultrasound for the Treatment of Brain Tumors
Rao, R., Patel, A., Hanchate, K., Robinson, E., Edwards, A., Shah, S., Higgins, D. M. O., Haworth, K. J., Lucke-Wold, B. P., Krummel, D. P., et al. (2023) · Tomography · doi:10.3390/tomography9030090 · Cited by 26
Stability and mechanism of threose nucleic acid toward acid-mediated degradation
Lee, E. M., Setterholm, N. A., Hajjar, M., Barpuzary, B., & Chaput, J. C. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad716 · Cited by 25
Ye, J., Pei, X., Cui, H., Yu, Z., Lee, H., Wang, J., Wang, X., Sun, L., He, H., & Yang, V. C.-M. (2018) · Journal of Industrial and Engineering Chemistry · doi:10.1016/j.jiec.2018.02.005 · Cited by 25
Poletaeva, J., Dovydenko, I. S., Epanchintseva, A. V., Korchagina, K. V., Pyshnyi, D. V., Apartsin, E. K., Ryabchikova, E. I., & Pyshnaya, I. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072096 · Cited by 25
Overcoming delivery barriers with LNPs
Jadhav, S. G., & Dowdy, S. F. (2021) · Nature Materials · doi:10.1038/s41563-021-00988-3 · Cited by 25
Self-citationMaguregui, A., & Abe, H. (2020) · ChemBioChem · doi:10.1002/cbic.202000009 · Cited by 26
Nano-ghosts: Novel biomimetic nano-vesicles for the delivery of antisense oligonucleotides
Oieni, J., Lolli, A., D’Atri, D., Kops, N., Yayon, A., van Osch, G. J. V. M., & Machluf, M. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.03.018 · Cited by 26
Progress and challenges of lyotropic liquid crystalline nanoparticles for innovative therapies
Silvestrini, A. V. P., Debiasi, B. W., Praça, F. S. G., & Bentley, M. V. L. B. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122299 · Cited by 24
Fasolo, F., Paloschi, V., & Mäegdefessel, L. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.11.021 · Cited by 24
Multiple regulatory roles of the transfer RNA-derived small RNAs in cancers
Zhang, Y., Gu, X., Li, Y., Huang, Y., & Ju, S. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.02.053 · Cited by 24
Pre-RNA splicing in metabolic homeostasis and liver disease
Jobbins, A. M., Yu, S., Paterson, H. A. B., Maude, H., Stavridi, A. K., Speck, C., Cebola, I., & Vernia, S. (2023) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2023.08.007 · Cited by 24
Review: N1-methyl-pseudouridine (m1Ψ): Friend or foe of cancer?
Rubio‐Casillas, A., Cowley, D., Raszek, M., Uversky, V. N., & Redwan, E. M. M. M. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.131427 · Cited by 27
As Technologies for Nucleotide Therapeutics Mature, Products Emerge
Beierlein, J. M., McNamee, L. M., & Ledley, F. D. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.10.017 · Cited by 24
Real‐Time Visualization of Lysosome Destruction Using a Photosensitive Toluidine Blue Nanogel
Zhang, W., & Tung, C. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201705697 · Cited by 24
Baljon, J. J., Dandy, A., Wang-Bishop, L., Wehbe, M., Jacobson, M. E., & Wilson, J. T. (2019) · Biomaterials Science · doi:10.1039/c8bm01643g · Cited by 24
Pandey, M., Ojha, D., Bansal, S., Rode, A. B., & Chawla, G. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101003 · Cited by 23
Xiong, Y., Zhang, Z., Liu, S., Shen, L., Zheng, L., Ding, L., Liu, L., Wu, L., Hu, Z., Li, L., et al. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s487598 · Cited by 24
Kim, H. J., Yi, S. W., Oh, H. J., Lee, J. S., Park, J. S., & Park, K.-H. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.05.035 · Cited by 23
Spermine-Based Poly(β-amino ester)s for siRNA Delivery against Mutated KRAS in Lung Cancer
Jin, Y., Adams, F., Isert, L., Baldassi, D., & Merkel, O. M. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00206 · Cited by 23
Challenging cancer targets for aptamer delivery
de Franciscis, V. (2017) · Biochimie · doi:10.1016/j.biochi.2017.09.014 · Cited by 23
The development of tertiary amine cationic lipids for safe and efficient siRNA delivery
Lin, Z., Bao, M., Yu, Z., Xue, L., Ju, C., & Zhang, C. (2019) · Biomaterials Science · doi:10.1039/c9bm00494g · Cited by 23
Skvortsova, Y. V., Salina, E. G., Burakova, E. A., Bychenko, O. S., Stetsenko, D. A., & Azhikina, T. L. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01049 · Cited by 23
Zhou, K., Johnson, L. T., Xiong, H., Barrios, S., Minnig, J. T., Yan, Y., Abram, B., Yu, X., & Siegwart, D. J. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01288 · Cited by 23
Metadata
- Authors
- Dowdy, S. F.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Dowdy, Steven F
- ORCID
- Dowdy, Steven F
- Venue
- Nature Biotechnology
- Published
- 2017-02-27
- Volume
- 35
- Issue
- 3
- Pages
- 222-229
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2594133976
- Cited by
- 1,139
- References
- 105
- Citations by year
- 2026: 103 · 2025: 130 · 2024: 147 · 2023: 133 · 2022: 130 · 2021: 141 · 2020: 104 · 2019: 88 · 2018: 120 · 2017: 41
- FWCI
- 9.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Keywords
- RNA therapeutics, RNA delivery, lipid bilayers, siRNA, microRNA, antisense oligonucleotides, aptamers, synthetic mRNA, CRISPR/Cas9
- MeSH terms
- RNAi Therapeutics, Animals, Cell Membrane, Humans, RNA, RNA Interference, Nanocapsules, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
